Join
Live feed
·
PRReleasevia Quantisnow
Rani Therapeutics Holdings Inc. logo

Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)

ByQuantisnow·Wall Street's wire, on your screen.
RANI· Rani Therapeutics Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RANI (Rani Therapeutics Holdings Inc.) and more on Quantisnow.